Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of rFXIII in Cardiac Surgery
NCT02239146Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Oct 2005
- Primary completion
- Jan 2008
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 5
01
Overview
Phase 1, randomised, double-blind trial in acquired bleeding disorder comparing rFXIII with Placebo (2 arms). Primary endpoint: Incidence and severity of adverse events. Started Oct 2005; status: completed.
02
Drugs
catridecacog
03
Conditions
acquired bleeding disorder
Beyond the preview
Go deeper on NCT02239146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02239146.